Johnson & Johnson (JNJ)
| Market Cap | 372.63B |
| Revenue (ttm) | 87.70B |
| Net Income (ttm) | 14.68B |
| Shares Out | 2.41B |
| EPS (ttm) | 6.04 |
| PE Ratio | 25.62 |
| Forward PE | 15.33 |
| Dividend | $4.96 (3.21%) |
| Ex-Dividend Date | Nov 26, 2024 |
| Volume | 7,345,762 |
| Open | 152.59 |
| Previous Close | 154.00 |
| Day's Range | 152.35 - 155.33 |
| 52-Week Range | 143.13 - 168.85 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 175.64 (+13.49%) |
| Earnings Date | Oct 15, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, Johnson & Johnson's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $175.64, which is an increase of 13.49% from the latest price.
News
J&J's skin disease drug meets main goals of late-stage study
Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psori...
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoi...
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conferen...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wild...
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facili...
2 Of The Cheapest, High-Quality Dividend Stocks On The Market
In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth ...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant ...
Johnson & Johnson: Tracking Well Above The Industry
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year,...
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the ...
Johnson & Johnson Enters Oversold Territory
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs
November's top-yielding Aristocrats include Franklin Resources, Amcor, Hormel, and Kenvue, meeting the dogcatcher ideal of dividends from $1K invested exceeding single share prices. Analysts forecast ...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat bef...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma
If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before th...
My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%
I will highlight 10 high dividend yield companies which, I believe, are worth considering investing in for November 2024. Each company could increase your portfolio's ability to generate dividend inco...
US FDA approves Johnson & Johnson's device for heart condition
The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of heart condition, the company said on Thursday.
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
TAIPEI and SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectiou...
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® c...
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson &...
Two Strategic Dividend Picks: One For Dividend Income And One For Dividend Growth
I have added Brookfield Renewable Partners and Linde to The Dividend Income Accelerator Portfolio, increasing the portfolio's allocation to the Materials and the Utilities Sectors. After their inclusi...
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression) 23 abst...